If a patient has a mutation that disables thromboxane production in platelets, which consequence follows during vascular injury?

💡 Explanation

Thromboxane A2 (TXA2) is a key mediator for platelet aggregation because it promotes the activation of other platelets and increases their adherence to the injury site. Therefore, disabling its production impairs platelet aggregation, rather than accelerating other coagulation pathways.

• Why does prolonged glucocorticoid treatment, such as for chronic asthma, increase the risk of osteoporosis?
• If a marathon runner experiences muscle fatigue primarily in their quadriceps toward the end of a race despite adequate hydration, which process is most likely responsible?
• A patient with cystic fibrosis exhibits abnormally thick sebum production affecting their skin's antimicrobial defense. Which mechanism best explains why their skin becomes more susceptible to bacterial infections?
• Why does increased thyroid hormone production, as seen in Graves' disease, lead to tachycardia (rapid heart rate)?
• If a marathon runner only consumes electrolyte-free water during a race, which consequence follows regarding plasma osmolality and ADH secretion?
• A patient undergoes chemotherapy, leading to bone marrow suppression. Which risk increases as the patient's bone marrow cellularity decreases, resulting in aplastic anemia?